Nested Therapeutics

China-based HitGen Inc. (SHA: 688222) has announced a research service agreement with Cambridge, Massachusetts-based precision medicine biotech Nested Therapeutics, Inc. Under the agreement, HitGen will leverage its DNA-encoded library (DEL) technology platform to identify hits against targets of interest for Nested. This collaboration combines HitGen’s expertise in DEL technology with…